On-treatment mortality predictors in chronic hepatitis B patients experiencing severe acute exacerbation: a prospective observational study

Table 3 The changes (∆) of clinical parameters from baseline to week 2 in different outcomes and treatment groups

	All	Survival	Mortality	p	Telbivudine	Entecavir	p
Patient no	21	17	4		9	12
ALT	−1161 (−2313-+106)	−1161 (−2313-+106)	−890 (−2057- -44)	1.000	−1383 (−2313-+106)	−547.5 (−2057- -30)	0.256
Bilirubin T	−0.4 (−9.1-+12.2)	−1.2 (−9.1-+11.5)	8.05 (5.9-12.2)	0.009	−0.9 (−6-+11.5)	−0.3 (−9.1-+12.2)	0.722
Creatinine	0.22 (−0.1-+2.33)	0.08 (−0.10-+0.87)	0.49 (0.23-2.33)	0.049	0.22 (−0.09-+0.87)	0.27 (−0.1-+2.33)	0.594
eGFR
MDRD	−23 (−162-+58)	−16 (−72-+58)	−85.5 (−162- -36)	0.008	−23 (−99-+23)	−23 (−162-+58)	0.749
CKD-EPI	−16.1 (−65.2-+12.6)	−6.0 (−65.2-+12.6)	−35.5 (−51.3- -21.7)	0.049	−21.1 (−65.2-+6.81)	−13.0 (−51.3-+12.6)	0.776
INR	−0.3 (−1.0-+0.9)	−0.3 (−1.0-+0.9)	−0.4 (−0.5-+0.7)	0.318	−0.3 (−0.6-+0.9)	−0.3 (−1.0-+0.7)	0.971
AFP	151.5 (−140.7-+2326.6)	184.2 (−110.2-+2326.6)	−73.2 (−140.7- -5.8)	0.057	184.2 (−5.8-+1385.9)	101.2 (−140.7-+2326.6)	0.386
HBV DNA (log₁₀ cps/ml)	−3.27 (−5.47- -0.55)	−3.4 (−5.5- -0.6)	−1.4 (−1.8- -1.0)	0.074	−3.4 (−5.0- -1.0)	−3.0 (−5.5- -0.6)	0.922
MELD score	−1.0 (−11-+14)	−1.0 (−11-+14)	0.0 (−1-+12)	0.344	−1.0 (−6-+14)	−0.5 (−11-+12)	0.775

Data shown as median (range); eGFR estimated glomerular filtration rate, MDRD modification of diet in renal disease (mL/min/1.73m²), CKD-EPI Chronic Kidney Disease Epidemiology Collaboration (mL/min/1.73m²), INR international normalized ratio, AFP alpha-fetoprotein, MELD model for end-stage liver disease.

ISSN: 1756-0500